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Introduction 
 
The nephrotic syndrome is a kind of disorder aris-
ing from extreme protein leakage from the blood-
stream into the urine because of renal damage (1). 
Hyperlipidemia is a disorder, which happens 
alongside this disease (2). The common 
dyslipidemias in nephrotic syndrome are Hyper-
cholesterolemia, increases of low-density lipopro-
tein-cholesterol (LDL-C) and very low-density 
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lipoprotein-cholesterol (VLDL-C). Consequently, 
these disorders in lipid metabolism result in higher 
risk of cardiovascular diseases that shows the im-
portance of lipid metabolism control in this dis-
ease. Among the substances that have the capacity 
to control cardiovascular diseases through changes 
in lipid metabolism, phyto-estrogens have an im-
portant role. Food phyto-estrogens are a subgroup 
of flavonoids that have beneficial effects on hu-
man health. This group comprises of several sub-
groups of non-steroid estrogens including isofla-
vones and lignans having been widely distributed 
among plants (3). Isoflavones (genistein and di-
adzein) are the most significant groups to have 
been widely undergone study. However, these iso-
flavones exist only in soybeans and several other 
legumes (3). The beneficial effects of dietary soy 
protein on the serum lipid concentrations have 
been shown in many studies on animal and on 
human cells (4-7). However, it is not exactly clear 
yet that these effects be mediated through the iso-
flavones such as genistein or not.  
Carnitine is bio-synthesized by two amino acids 
[lysine and methionine] (8), and is necessary for 
transporting fatty acids from cytosols to mito-
chondria (9). Recently, many studies have focused 
on the role of carnitine in lipid metabolism. It has 
been proven that L-carnitine (a chemical structure 
of carnitine) is able to bring down the levels of 
triglycerides within rats’ tissues and plasma (10) 
but the mechanisms of its effects are not obvious 
yet. 
Hydroxy Methyl Glutharyl-CoA Reductase 
(HMG-CoA) is the enzyme involved in synthesiz-
ing cholesterol and Low Density Lipoprotein Re-
ceptor (LDLr), which would be the LDL-C lipo-
protein receptor in the liver: they are effective in 
the metabolic regulation of lipid and the liver cho-
lesterol (11). Genistein gives rise to some level of 
LDLr gene expression (12, 13) while reducing the 
HMG-COA Reductase gene expressivity (13, 14). 
However, rare studies have ever been conducted 
as for the effect of L-carnitine on HMG-COA 
Reductase and LDLr; their resultant outcome is 
mostly paradoxical (15). The conducted investiga-
tions over the issue of the twin effect of genistein 
and L-carnitine on these two mentioned gene ex-
pression are extremely limited. We investigated 
the twin effect of genistein and L-carnitine to 
know if any joint pathway or synergistic effects in 
the pathways do exist or not.  
Lack of a comprehensive study regarding this is-
sue has caused the design of the present study 
with the aim of delving into the single separate 
and/or twin effects of genistein and L-carnitine 
on the HMG-COA Reductase and LDLr gene 
expression among the rats afflicted by the experi-
ential nephrotic syndrome.  
 
Material and Methods 
 
Animals and experimental diets  
Male Sprague–Dawley rats at 8-12 weeks of age 
were housed individually in a room with con-
trolled temperature (20–22 °C), humidity (55–
65%) and lighting (from 0700 to 1900 h) and fed 
assigned experimental diet (AIN 93 M diet) (Table 
1) (16). After 7 days of acclimatization, the rats 
were randomly divided into five groups consisting 
of 10 animals each with similar mean body 
weights (300±50 g) by randomized block design 
method: normal control (NC), patient control 
(PC), L-carnitine (LC), genistein (G), L-carnitine-
genistein (LCG).  
 
Chemical reagents and Intervention 
All groups received their own experimental diets 
during the study (8 weeks). We used carboxyme-
thyl cellulose (CMC, Sigma Chemical Co.) as a 
solvent for genistein and L-carnitine. In addition, 
CMC was used for gavage feeding of control 
groups. NC group received 50 mg/kg body weight 
CMC by gavage for 8 weeks; PC group received 
CMC for 8 weeks while receiving single dose of 
7.5 mg/kg body weight Adriamycin (Doxorubicin, 
Pharmacia Italia SPA Co.)-an antibi-
otic/antineoplastics drug with nephrotoxic side 
effect- through tail vein at the end of week 2 to 
induce nephrotic syndrome (17), hereafter, we 
keep on gavage-feeding of rats with 50 mg/kg 
body weight CMC for 6 weeks. LC, G and LCG 
groups were similar to PC except receiving 50 
mg/kg body weight L-carnitine (99%, Karen 
Pharma & Food Supplement Co.), 50 mg/kg body 
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weight genistein (99%, LC-laboratories Co.) and 
50 mg/kg body weight L-carnitine plus 50 mg/kg 
body weight genistein, respectively, that were dis-
solved in CMC instead of CMC. 
 
Table1: Composition of experimental diet (AIN-93 
modified diet for rodents) 
 
Ingredient g/kg diet 
Cornstarch 465.692 
Casein (>85% protein) 140.000 
extrinized cornstarch 
(90-94% tetrasaccharides)1 
155.000 
Sucrose 100.000 
Soybean oil (no additives) 40.000 
Fiber2 50.000 
Mineral mix 35.000 
Vitamin mix 10.000 
L-Cystine 1.800 
Choline bitartrate (41.1% choline)3 2.500 
Tert-butylhydroquinone 0.008 
 u/kg diet 
Total energy4 kcal 3601.0 
protein% 14.1 
CHO% 75.9 
fat% 10.0 
1Dyetrose (Dyets, Bethlehem, PA) and Lo-Dex 10 
(American Maize, Hammond, IN) meet these specifica-
tions. An equivalent product may also be used./ 2Solka-
Floc®,200 FCC (FS&.D, St. Louis, MO) or its equivalent 
is recommended./ 3Based on the molecular weight of the 
free base./ 4The estimate of caloric content was based on 
the standard physiological fuel values for protein, fat, and 
carbohydrate of 4, 9 and 4, respectively. 
 
Animals were maintained ad libitum on assigned 
experimental diet and water during the experiment 
and Dietary intake and body weight were recorded 
every day and weekly, respectively.  
This study was approved by the review board of 
animal ethics Tehran University of Medical Sci-
ences and we followed the institute's guidelines in 
the care and use of laboratory animals. 
 
Sample preparation 
During the study, urine samples were collected 
(spot urine method) at the end of weeks 2, 3 and 7 
and measured urine total protein and protein-to-
creatinine ratio from spot urine samples. Pyrogal-
lol-Red/Colorimetric End Point method and 
Taussky et al. (18) & Owen et al. (19), modified 
method were used for measuring of protein and 
creatinine, respectively. After 8 weeks, the animals 
were sacrificed after overnight fasting by bleeding 
from the abdominal aorta under diethyl ether an-
esthesia. Blood was collected from abdominal aor-
ta and livers were surgically excised. The blood 
was allowed to coagulate and centrifuged at 1,100 
rpm for 15 minutes, and serum was stored at -
20 °C until albumin analysis (salt fractionation 
method). Liver tissues were collected and immedi-
ately frozen in liquid nitrogen, and stored at -
80 °C until analysis.  
 
RNA Extraction from Liver and cDNA Syn-
thesis  
Cytoplasmic RNA was extracted and purified us-
ing RNeasy Plus Mini Kit (Qiagen, Valencia, Calif., 
USA) according to the manufacturer’s protocol. 
Quantity and purity of extracted RNA was 
checked by NanoDrop spectrophotometer 
(NanoDrop Technologies, Wilmington, Del., 
USA). A ratio of A 260/280 between 1.9–2.1 was 
taken into account as pure RNA (Fig. 1). Single-
strand cDNA was synthesized using QuantiTect 
Reverse Transcription Kit (Qiagen). 
 
Real-time PCR for Gene Expression  
PCR primers for HMG-COA Reductase and 
LDLr genes and 18-S gene (as housekeeping) were 
designed by Primer express 3 software (Applied 
Biosystem, Foster city, CA, USA) and purchased 
from Metabion (Table 2).  
PCR reactions were briefly as follows (20, 21); 
PCR proceeded in special optical tubes in 48- re-
action plates (MicroAmp Optical, ABI) with 20 µl 
reaction mixture containing 10µl Power SYBR® 
Green PCR Master Mix (Applied Biosystem, Fos-
ter city, CA, USA), 7µl DEPC treated water, 0.5µl 
forward primer, 0.5µl reverse primer and 2µl 
cDNA as template. The wells were sealed with 
optical adhesive film (Applied Biosystem, Foster 
city, CA, USA), and the plate was centrifuged for 
a few seconds at high speed. Amplification condi-
tions were performed using the standard two-step 
run protocol; step 1:10s at 95 °C, step 2: 40 cycles 
of 15s at 95 °C plus 1s at 60 °C.  
Yousefinejad et al.: Effect of Genistein and L-Carnitine and Their Combination on Gene Expression … 
Available at:    http://ijph.tums.ac.ir                                                                                                      1342 
 
 
Fig. 1: NanoDrop spectrophotometer of the extracted RNA 
 
After completion of amplification cycles, melt curve 
was generated to verify if a single gene product had 
been amplified. For each gene, mRNA expression 
level was normalized to the level of 18-S. The fold 
changes of genes expression were computed using 
the comparative Ct (2–ΔΔCt) method. 
 
Statistical analysis 
Statistical analysis was done using SPSS 18.0 for 
windows (Chicago, IL, USA). Normality of all da-
ta was checked by Kolmogorov-Smirnov test and 
histogram. Data was expressed as mean ± SD. 
Comparison of quantitative variables between dif-
ferent groups were evaluated by one-way ANO-
VA, followed by post hoc Scheffé test. P-value < 
0.05 was considered statistically significant. 
 
Results 
 
Body weight and food intake 
As shown in Table 3, there were not any statisti-
cally significant differences between groups in ini-
tial weight, but final weight and weight gain of the 
patient groups was significantly less than the NC 
group (P<0.05). The PC group did not show any 
statistically significant differences compared with 
LC, G and LCG groups in all these variables (Ta-
ble 3). 
 
Table 2: Primer sequences for real-time PCR 
 
Gene  Sequence Length TM CG% 
HMG-COA 
Reductase 
Forward 5´-GTGGGAACGGTGACACT TA-3´ 
Reverse 5´-CTTCAAATTTTGGGCACTCA-3´ 
19 
20 
49.47 
49.14 
53 
40 
LDLr 
 
Forward 5´-CTGGCGGTAGACTGGATC-3´ 
Reverse 5´-CAATCTGTCCAGTACATGAAGC-3´ 
18 
22 
50.97 
52.39 
61 
45 
18-S 
 
Forward 5´-CCATCCAAT CGGTAGTAGC-3´ 
Reverse 5´-GTAACCCGT TGAACCCCATT-3´ 
19 
20 
49.61 
50.05 
53 
50 
 
Table 3: Body weight and food intake in rat fed experimental diets for 8 weeks 
 
Variable NC group PC group LC group G group LCG group P valuea 
Initial weight (g) 296.50±25.50 291.50±28.19 294.77±23.62 303.22±34.23 312.00±26.25 0.501 
Final weight (g) 355.30±18.43 283.30±34.13b 277.88±48.73b 283.44±47.47b 263.14±67.88b 0.001 
Weight gain (g/day) 1.04±0.45 -0.14±0.50b -0.36±0.83b -0.34±0.58b -0.87±0.77b 0.00 
Food intake (g/day) 20.36±0.73 16.73±0.49b 16.36±1.16b 15.33±1.10b 15.16±0.40b 0.00 
Protein Intake (g/day) 2.55±0.09 2.10±0.06b 2.05±0.14b 1.92±0.14b 1.90±.05b 0.00 
Energy intake (Kcal/day) 73.34±2.65 60.25±1.77 b 58.93±4.20 b 55.21±3.98 b 54.61±1.45 b 0.00 
Values are means±SD./ aOne-way ANOVA between groups./ bValues for PC, LC, G and LCG groups are significantly different 
compared with NC group by post hoc Scheffé test at P<0.05.  
Iran J Public Health, Vol. 44, No.10, Oct 2015, pp.1339-1347  
1343                                                                                                    Available at:  http://ijph.tums.ac.ir 
Serum albumin, Proteinuria and protein-to-
creatinine ratio 
There were not any statistical significant differ-
ence between groups in proteinuria and urine pro-
tein-to-creatinine ratio at week 2, but the differ-
ences were significant between PC group and LC, 
G and LCG groups at week 7 (Table 4).  
 
Table 4: Proteinuria and protein-to-creatinine in experimental groups at weeks 2, 3 and 7 and serum albumin 
 
Variable NC group PC group LC group G group LCG group P valuea 
Week 2: 
Proteinuria (mg/dl)  
107.70±4.92 111.85±5.92 102.00±48.74 105.11±28.94 98.00±9.38 0.877 
Week 3: 
Proteinuria (mg/dl) 
107.50±6.36 671.14±180.28b 273.00±99.73c 384.66±237.18b 210.25±131.77c 0.00 
Week 7: 
Proteinuria (mg/dl) 
103.90±22.65 1864.00±298.27b 328.50±27.87c 680.88±348.82bc 400.25±120.13c 0.00 
Week 2: 
Urine protein-to-creatinine ratio 
2.96±1.26 3.96±0.71 1.85±0.28 3.74±1.82 3.67±1.47 0.104 
Week 3: 
Urine protein-to-creatinine ratio 
3.39±1.12 29.98±7.41b 18.70±30.71 14.38±7.92 5.88±.3.71c 0.001 
Week 7: 
Urine protein-to-creatinine ratio 
3.87±1.30 71.48±17.20b 22.97±3.19c 38.11±19.59bc 20.67±21.28c 0.00 
Serum albumin 3.63±0.25 1.32±0.34b 2.73±0.23bc 1.47±0.63b 2.86±1.35c 0.00 
Values are means±SD. 
aOne-way ANOVA between groups. 
bValues for PC, LC, G and LCG groups are significantly different compared with NC group by post hoc Scheffé test at P<0.05. 
cValues for LC, G and LCG groups are significantly different compared with PC group by post hoc Scheffé test at P<0.05. 
 
HMG-COA Reductase and LDLr Expression 
in hepatocyte-Extracted mRNA 
Expression of HMG-COA Reductase mRNA 
between the LC, G, LCG groups and the PC 
group had statistically significant differences 
(P<0.001, Table 5). L-carnitine and genistein 
could down-regulate HMG-COA Reductase and 
twin-effects of them had a synergistic effect, 
however the differences between the LC, G, LCG 
groups were not statistically significant. As to the 
relative gene expression of LDLr, significant 
differences were not observed between the 
groups, but there were statistically significant 
differences between LC, G, LCG groups and PC 
group in ΔCT (P<0.001, Table 5).  
 
Table 5: ΔCT and mean of HMG-COA Reductase and LDLr gene expression in hepatocytes 
 
Variable NC group PC group LC group G group LCG group P valuea 
Δ-CT of HMG-COA Reductase 14.52±1.72 13.29±0.48 13.32±1.94 13.14±1.96 12.68±2.38 0.371 
Mean of gene expression of 
HMG-COA Reductase 
1.41±1.32 2.66±0.88 0.78±0.61c 0.24±0.20bc 0.23±0.15bc 0.000 
Δ-CT of LDLr -0.16±0.48 3.31±1.88b -0.33±0.66c -0.82±1.24c -1.14±2.21c 0.000 
Mean of gene expression of LDLr 1.24±0.83 0.19±0.08b 0.89±0.67 1.09±0.49 0.74±0.34 0.035 
Data are reported as means ± SD. ΔCT = CT of target gene – CT of 18S. 
aOne-way ANOVA between groups./ bValues for PC, LC, G and LCG groups are significantly different compared with NC 
group by post hoc Scheffé test at P<0.05./ cValues for LC, G and LCG groups are significantly different compared with PC 
group by post hoc Scheffé test at P<0.05.  
 
Discussion 
 
Over the separate effects of genistein and L-car-
nitine, we have studied their cumulative twin ef-
fects, as well, in Sprague-Dawley rats. As shown in 
Table 3, the final weight in addition to the weight 
gain have been lower and negative in all patient 
groups in comparison with the NC group; the rea-
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sonable cause for this phenomenon has been rats’ 
affliction by the nephrotic syndrome which has 
consequently followed by reductions in food and 
energy intakes among these groups. In spite of 
receiving less protein in the patient groups as 
compared with the NC group, the proteinuria and 
the urine protein-to-creatinine ratio have been 
higher in the patient groups versus the NC group, 
as brought out in Table 4: this indicates their hav-
ing been caught by the nephrotic syndrome and 
the protein tissue lysis leading to higher weight 
loss among these groups, although such increase 
amongst a number of patient groups has not been 
statistically significant.  
 
Genistein Effect on LDLr and HMG-COA 
Reductase Gene Expression 
Insulin and glucagon are key controllers for the 
matter of biosynthesizing cholesterol and triglyc-
eride within the liver: they exert their biological 
controlling influence through some changes in the 
level of activity and/or expressing gene levels in-
volved in the synthesizing and/or absorbing cho-
lesterol; the same influence can also be exerted by 
means of synthesizing fatty acids. Such genes tran-
scription controlling would be accomplished 
through the means of a family of transcription 
factors by the name of SREBP (22). Genistein 
possesses the capability to increase the glucagon 
to insulin ratio (23), thus giving rise to some in-
crease not only in the level of SREBP-2 expres-
sion, but also in its activity (24). SREBP-2 would 
preferably hook on to those promoters of the 
number of genes involved in absorbing and bio-
synthesizing cholesterol [including HMG-CoA 
Reductase and (LDLr) LDL recipient] (11). In fact, 
the category of isoflavones present in soy protein 
can activate SREBP-2 so that, as a result, the se-
rum cholesterol clearance could well increase (25). 
When the cholesterol level comes down in the 
cells belonging to animals fed with soy protein, 
the mature nuclear SREBP-2 form content in-
creases by up to the level of 119% in comparison 
with the rats dieted on casein (26) which in itself 
would lead to some increase in the level of LDLr 
gene expression (27). Borradaile et al. have also 
conducted a study on the human liver cells 
(HepG2) to show that genistein causes increase in 
the levels of LDLr mRNA by 3 to 6 times; this 
means that they increase the absorption and the 
lysis of marked LDLs statistically significantly (13). 
All the same, it should not be far from notice that 
such effects might actually be independent of the 
insulin to glucagon ratio (28).  
The isoflavones’ effect, especially that of genistein, 
on HMG-COA Reductase turns out to be para-
doxical. There are a number of studies indicating 
that genistein could give rise to increase in LDLr 
gene expression to be followed by HMG-COA 
Reductase gene expression within the human 
DLD-1 cancerous colon cells (12, 29).  
Our own investigation has shown that genistein 
causes some reduction in HMG-COA Reductase 
gene expression: this is in contrast with the PC 
group. Such reduction was even greater than that 
of the L-carnitine recipient group, despite the fact 
that the said difference did not prove statistically 
significant (Table 5). Moreover, the LDLr expres-
sion in the group receiving genistein was actually 
higher as compared with the PC group, and even: 
as contrasted with L-carnitine; however, these dif-
ferences were not statistically significant, though 
the Δ-CT difference in between the G group and 
the PC group turned out to be statistically signifi-
cant (Table 5).  
 
L-carnitine Effect on LDLr and HMG-COA 
Reductase Gene Expression  
Dyslipidemia is generally common among patients 
with renal ailments, specifically among those af-
flicted by the nephrotic syndrome. Nearly 40 per-
cent of those patients undergoing haemodialysis 
are gripped by some sort of dyslipidemia: the ma-
jority of them are afflicted by hyperlipidemia type 
IV and plasma HDL-C reduced levels (30). The 
progressing and advancement of dyslipidemia 
among such patients are themselves under the in-
fluence of a number of various parameters such as 
carnitine shortage, leading to actual disorders in 
the process of lipid metabolism (31, 32). The car-
nitine can significantly bring down the levels of 
rats’ tissues and plasma triglyceride (33). Still, and 
overall systematic review would indicate that car-
nitine has no statistically significant effects on tri-
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glyceride, cholesterol, and their probable deriva-
tives (34). The carnitine supplement has turned 
out to be effective in adjusting the lipid profile 
among those patients whose level of triglyceride 
has been above the 200 mg/dl or the HDL-C lev-
el has actually been below 35 mg/dl (35).  
In the present study, L-carnitine could well have 
caused some statistically significant decrease in 
HMG-COA Reductase gene expressivity in com-
parison with the PC group in spite of the fact that 
such reducing effect has not been up to the group 
receiving genistein. In addition, the LDLr expres-
sion because of receiving L-carnitine went on the 
increase in comparison with the PC group: alt-
hough such an increase was not statistically signifi-
cant, the difference in Δ-CT did prove significant 
(Table 5).  
Very limited studies are available regarding the 
effect of carnitine on the gene expressions of the 
two genes of HMG-COA Reductase and LDLr. 
Evaluation has been made in Mondola’s et al. in-
vestigation into the effect of carnitine on choles-
terol metabolism and HMG-COA Reductase ac-
tivity in rats’ liver cells where it has been shown 
that L-carnitine could well rein in the HMG-COA 
Reductase activity and also increase the bonding 
of LDL on two the liver cells (15).  
 
The Twin Effect of Genistein and Carnitine 
on LDLr and HMG-COA Reductase Gene 
Expression  
In our study, the synergistic effect of genistein and 
L-carnitine on the expressivity of both genes have 
actually been observed, although this effect turned 
out to be statistically significant nearly as far as 
comparison was made in between HMG-COA 
Reductase vs. the PC group. Δ-CT gene LDLr, 
too, showed of itself some significant synergistic 
effect (Table 5). Similar studies concerning the 
twin effect of genistein and carnitine on these two 
genes’ expression are skimpy to such a degree that 
their availability would prove difficult.  
 
Conclusion 
 
A 6-week gavaging with L-carnitine and genistein 
increased the HMG-COA Reductase and LDLr 
gene expression and had synergistic effects in rats 
with nephrotic syndrome; however, the changes 
were statistically significant only for HMG-COA 
reductase. It seems genistein is more effective on 
these gene expressions in comparison with L-car-
nitine. These finding could warrant future studies 
to determine the therapeutic effects of these sup-
plements on nephrotic syndrome and lipid me-
tabolism management. 
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